title: Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
authors.affiliation: University of California, San Francisco Cancer Center, San Francisco, California 94115-1710, USA. jpark@cc.ucsf.edu
authors.forename: John W
authors.initials: JW
authors.lastname: Park
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kerbel
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: J Carl
authors.initials: JC
authors.lastname: Barrett
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Chabner
authors.forename: David R
authors.initials: DR
authors.lastname: Parkinson
authors.forename: Jonathan
authors.initials: J
authors.lastname: Peck
authors.forename: Raymond W
authors.initials: RW
authors.lastname: Ruddon
authors.forename: Caroline C
authors.initials: CC
authors.lastname: Sigman
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Slamon
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012109:Research Support as Topic
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor